Compare Beyond Meat Inc (BYND) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Beyond Meat Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Beyond Meat Inc trades at $0.4 (market cap $215.41M), while Vertex Pharmaceuticals Incorporated trades at $525.14 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 623.2× Beyond Meat Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| BYND | VRTX | |
|---|---|---|
Market Cap | $215.41M | $134.25B |
Sector | Consumer Staples | Health |
52-Week High | $3.62 | $529.65 |
52-Week Low | $0.42 | $376.62 |
Enterprise Value | $455.69M | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYND trades at $0.40, down 22.6% amid a 30:1 reverse stock split announced August 14, 2026. Despite beating Q2 2026 EPS estimates, revenue has declined from $419M in 2022 to $275M in 2025. The stock shows bearish technical signals with oversold RSI readings. Analyst consensus is heavily bearish with 57% sell ratings, reflecting concerns over cash burn and market positioning.
The outlook remains challenging with declining revenues and negative operating cash flow. Investment opportunity exists if turnaround efforts succeed in international markets, but risks include persistent cash burn, competitive pressures, and execution uncertainty. The reverse split addresses listing requirements but doesn't resolve fundamental business challenges.
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
